Biospark LeaderTalk Dr. Li PENG From Palleon Pharma

In this seventh episode of the BioSpark LeaderTalk Series, we present an exclusive interview titled "Women in Power: How two female scientists are transforming Nobel-winning science to next-gen cancer drugs."
We are honored to host Dr. Li Peng, PhD, the Chief Scientific Officer of Palleon Pharma. Dr. Peng shares her journey and professional insights into the cutting-edge field of oncology, discussing how foundational, Nobel-winning scientific discoveries are being translated into life-saving cancer therapeutics.

#BioSpark #LeaderTalk #WomenInScience #PalleonPharma #CancerResearch #DrugDevelopment #Biotech #Oncology #WomenInSTEM #Pharmaceuticals #NobelScience #BiotechLeadership

BioSpark Group is a non-profit corporation registered in Massachusetts in the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation. http://biospark.org/

Видео Biospark LeaderTalk Dr. Li PENG From Palleon Pharma канала BioSpark Group

BioSpark Group LeaderTalk Series Dr. Li Peng Palleon Pharma Women in Science Cancer Drug Development Biotechnology Nobel Prize Science Oncology Pharmaceutical Industry Women in Power CSO Interview Next-Gen Therapeutics Female Scientists.

Комментарии отсутствуют

Информация о видео

3 февраля 2023 г. 7:31:01

01:01:59

BioSpark Group

Теги

Правообладателям

Жалоба на материал Недопустимый материал Нарушение авторских прав

Комментарии

Другие видео канала

Biospark LeaderTalk Dr. Li PENG From Palleon Pharma

Terns Pharma Stock Soars 250% on Unprecedented TERN-701 Clinical Signals

ASCO2023 Recap: The winners, losers, and black horses #ASCO23 #Oncology #Keytruda #PD1 #TIGIT

BioSpark沙龙：新冠病毒的治疗与药物研发（2020.02.15）

CytomX Phase 1 Data: Is Varseta-M the Breakthrough Masked ADC for Colorectal Cancer?

BioSpark Webinar: Lunar New Year Special Event, 2019 in Review, 2020 Outlook

Current Status of Gene Editing Therapies for Sickle Cell Disease and β-Thalassemia (Ethan Xu)

Saving an Infant with CRISPR: The World's First Personalized In Vivo Base Editing Therapy

Targeting ITK: How Corvus Soquelitinib (CPI-818) is Revolutionizing Atopic Dermatitis Treatment

Nature publishes Phase 1 Parkinson’s allogeneic cell therapy trial results (2025/04).

BioSpark Scientific Salon (2021-06-05): How Synthetic Lethality Powers Cancer Therapy?

【BioSpark Innovation Talk】Multimodal Mapping as a Foundation for Virtual Cell

Eloralintide in Focus: Eli Lilly’s Amylin Agonist Shows Promising Phase 2 Obesity Data (11/2025)

J&J’s Breakthrough: Teclistamab + Daratumumab Smashes PFS Records in Multiple Myeloma

BioSpark聊人工智能: 自然语言处理技术在制药产业的应用

Kymera’s Oral STAT6 Degrader: Dupixent-Like Efficacy in Atopic Dermatitis

Merck’s HIF-2α Inhibitor: Analyzing the LITESPARK-012 Setback and the Future of RCC Treatment

Is KRAS Finally Druggable? Pancreatic Cancer Breakthroughs on Daraxonrasib by Revolution Medicines

ASCO2023 Preview: Market-moving data, Rise of Asian biotech, and Practice-changing trials

Oral Macrocyclic Peptides: Merck’s Enlicitide Breakthrough & Novartis Deals

Viking VK2735 Phase 2a Deep Dive: Compelling Efficacy vs. Safety Concerns